Alzai Health Corp.
ALZI.V
Toronto Stock Exchange Ventures0.37
CAD
- -
- -
ISIN
CA02262P1036
CUSIP
02262P103
Return %
Stock
S&P500
1Y
-11.90
16.05
3Y
-11.90
77.49
5Y
-11.90
72.82
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- CEO
- Hayim Raclaw
- Sector
- Technology
- Industry
- Software - Application
- Address
- 22 Adelaide Street West Toronto ON Canada M5H 4E3
- IPO Date
- Jun 9, 2026
- Website
- alzaihealth.com
- Similar Companies
- Business
- Alzai Health Corp. operates as a healthcare technology company developing artificial intelligence-driven, non-invasive disease-risk identification solutions using routine healthcare data. The Company’s principal offering is an AI-based Alzheimer’s disease and mild cognitive impairment risk-screening platform designed to identify individuals at elevated risk before clinical diagnosis; its solutions analyze common medical-record biomarkers and are designed for integration with electronic medical record systems, cloud environments and enterprise healthcare platforms. Alzai provides pre-screening tools for clinical-trial sponsors, pharmaceutical companies, contract research organizations, research institutions and service providers to identify potentially suitable trial participants, reduce screen-failure rates and support recruitment; primary-care and health-system risk-assessment solutions intended to support early detection, preventive intervention and care optimization; and related data-integration, implementation, tuning and professional services. The Company generates revenue through solution licensing and professional services, and may employ pay-per-screen and annual-licensing models for healthcare-system, diagnostic, laboratory and insurance-market applications. Alzai targets healthcare providers, health plans and other public and private payors, pharmaceutical and clinical-research organizations, health systems and individuals, with an initial concentration on Alzheimer’s disease screening and clinical-trial applications. Incorporated in 2024 and headquartered in Toronto, Ontario, Canada, Alzai Health Corp. is listed on the TSX Venture Exchange under the symbol ALZI. Recent developments include the validation of its Alzheimer’s disease risk-identification models using a large-scale U.S. longitudinal healthcare dataset; a July 2026 strategic U.S. commercialization agreement with Centauri Health Solutions to market AI-driven Alzheimer’s risk stratification across Medicare Advantage and other value-based-care settings; an August 2026 memorandum of understanding with Linus Health to explore use of complementary technologies for early identification of Alzheimer’s disease risk and cognitive impairment; and a July 2026 exclusive worldwide license from MOR Research Applications Ltd., the technology-transfer company of Clalit Health Services and Yeda Research, for AI-driven liver-disease risk-identification technology, expanding the Company’s potential disease-screening portfolio.